PMGC Holdings Inc.
PMGC Holdings is a diversified holding company that acquires and grows businesses and assets across biotechnology, investment, specialty packaging and precision manufacturing. Its four wholly owned subsidiaries are Northstrive Biosciences, PMGC Capital, Pacific Sun Packaging and AGA Precision Systems. Northstrive develops biopharmaceutical assets, including EL-22 and preclinical candidate EL-32, engineered probiotics aimed at preserving muscle during weight-loss treatment. PMGC Capital invests, lends and pursues acquisitions of undervalued assets and companies. Pacific Sun Packaging designs and supplies custom and standard protective packaging for electronics and IT hardware components. AGA Precision Systems provides high-tolerance CNC milling and turning, mold manufacturing and machining of specialty metals for aerospace, defense and industrial customers. The businesses earn money through investment and lending activities, packaging sales and manufacturing services, while Northstrive is focused on developing its drug candidates. PMGC Holdings is headquartered in Newport Beach, California.
No enriched coverage for $ELAB in the last 7 days.
No SEC Form 4 filings for $ELAB in the last 30 days.
See all $ELAB insider activity →PMGC Holdings Inc. (ELAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 NorthStrive Biosciences Announces Results from EL-32 Preclinical Combination Study with Semaglutide and Plans for Next Phase of Development ● Study identifies preliminary lean-mass finding at the highest EL-32 dose while informing future preclinical development strat
PMGC Holdings' subsidiary NorthStrive Biosciences completed a preclinical study on EL-32, an engineered probiotic, in combination with semaglutide. The study found that high-dose EL-32 plus semaglutide showed more lean mass in mice than semaglutide alone, but results were dose-specific. NorthStrive plans further studies with lower semaglutide doses, focusing on lean mass and body composition. EL-32 is designed to target muscle preservation for GLP-1 weight loss treatments.
PMGC Holdings Inc. (ELAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Subscription Agreement for Secured Debentures of Nuclea Energy Canada Inc. On October 30, 2026, PMGC Holdings Inc. (the “Company”) entered into a Subscription Agreement (the “Subscription Agreement”) with Nuclea Energy Canada
Recent ELAB coverage spans corporate actions, mergers & acquisitions and financial news.
Early‑stage data may de‑risk the EL‑32 program but remains inconclusive; limited immediate price move expected.
Preclinical data suggests potential muscle‑preservation benefit, but limited efficacy and small scale keep impact modest.
The financing adds debt and potential dilution, likely exerting modest downside pressure on ELAB shares.
The SPAC sponsorship could provide upside for ELAB if the market values the new vehicle positively.
The agreement provides predictable, non‑dilutive cash flow but the amounts are modest relative to PMGC's balance sheet.
AlphAI scores every news story that mentions ELAB with an AI model for sentiment and relevance, and aggregates insider trades from PMGC Holdings Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
PMGC Holdings Inc. (ELAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 NorthStrive Biosciences Announces Results from EL-32 Preclinical Combination Study with Semaglutide and Plans for Next Phase of Development ● Study identifies preliminary lean-mass finding at the highest EL-32 dose while informing future preclinical development strat
PMGC Holdings' subsidiary NorthStrive Biosciences completed a preclinical study on EL-32, an engineered probiotic, in combination with semaglutide. The study found that high-dose EL-32 plus semaglutide showed more lean mass in mice than semaglutide alone, but results were dose-specific. NorthStrive plans further studies with lower semaglutide doses, focusing on lean mass and body composition. EL-32 is designed to target muscle preservation for GLP-1 weight loss treatments.
PMGC Holdings Inc. (ELAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Subscription Agreement for Secured Debentures of Nuclea Energy Canada Inc. On October 30, 2026, PMGC Holdings Inc. (the “Company”) entered into a Subscription Agreement (the “Subscription Agreement”) with Nuclea Energy Canada
PMGC Holdings (ELAB) completed a $100M SPAC IPO for NorthStrive Acquisition Corp I (NSAIU), targeting aerospace, industrial tech, and supply chain sectors. PMGC holds 21.4% of NSAI's Class A shares, aligning with future value creation. This marks the launch of PMGC's SPAC sponsorship platform.
PMGC Holdings Inc. (ELAB) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings ● Binding, interest-bearing payment plan converts PMGC’s 5% net sales royalty into scheduled monthly cash paym
PMGC Holdings Inc. (ELAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four AI-Discovered Compounds Toward Lead Nomination in Cardiac Disease and Obesity Pursuant to a First Amendment to the Development and License Agreement, NorthStrive Bi
NorthStrive Biosciences, a PMGC Holdings subsidiary (NASDAQ: ELAB), and Yuva Biosciences launched a 6-month Expansion Program to advance 4 AI-discovered compounds for cardiac disease and obesity. The program aims to nominate a lead and backup compound, with updated agreement terms and expanded rights.
PMGC Holdings Inc. (ELAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss Proposed Mice2Space spaceflight study would evaluate EL-22
PMGC Holdings (ELAB) signed a non-binding term sheet with Orbit2Orbit for space-based research, manufacturing, and a CAD $200,000 equity investment. The collaboration includes testing PMGC's drug candidates in microgravity and manufacturing spaceflight hardware. The deal is subject to final agreements and approvals.
PMGC Holdings Inc. (ELAB) terminated its planned acquisition of a 76% stake in a precision machining company after due diligence revealed lower-than-expected financial performance. The company reaffirmed its disciplined M&A strategy and is investing in aerospace & defense manufacturing, robotics, and automation to boost capacity and efficiency. PMGC is evaluating multiple acquisition opportunities and integrating portfolio companies to improve operational efficiency.
